Overview
Lobbying Costs
None declared
Financial year: Jan 2014 - Dec 2014
Lobbyists (Full time equivalent)
0.75 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Genzyme a SANOFI Company (Genzyme)
EU Transparency Register
2946627525-90 First registered on 17 Oct 2008
Goals / Remit
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Main EU files targeted
rare disease policies, pharmaceutical dossiers and use of biotechnology in health care
in particular in the context of and related to:
- REGULATION (EC) No 141/2000 of 16 December 1999 on orphan medicinal products
- COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS on Rare Diseases: Europe's challenges - Brussels, 11.11.2008 COM(2008) 679 final
- EU Net HTA Joint action
- EUCERD Joint Action
- IMIAddress
Head Office
Kendall Street, 500
Cambridge MA 02142
UNITED STATESEU Office
rue de la science 14
Brussels 1040
BELGIUM -
People
Total lobbyists declared
2
Employment time Lobbyists 50% 1 25% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
2014 numbers are under review
Person in charge of EU relations
Ms Vinciane Pirard (Director Public Affairs)
Person with legal responsibility
Mr David Meeker (CEO)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Member of BIO (US), PhARMA (US), EFPIA (EU), EBE (EU) & EuropaBio (EU)
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2014 - Dec 2014
Lobbying costs for closed financial year
None declared
Other financial info
The estimated costs for 2014 are under review ( 26:03:2015)
-
EU Structures
Groups (European Commission)
Expert Group on Rare diseases
ACC
None
Groups (European Parliament)
None
Communication activities
None
Other activities
To facilitate access to treatments for high, unmet medical need especially rare genetic diseases and multiple sclerosis.
To support all aspects supporting Europe’s Innovation and Research & Development activities in healthcare.
Meetings
Meetings
None declared